Sergio Cifuentes Canaval, Medical Oncologist at Las Américas Auna Clinic, shared a post on X:

“Anthracyclines in early HR+/HER2– BC: still a role?

This analysis comparing EC-T vs TC across Oncotype DX RS subgroups shows no significant benefit of adding anthracyclines for DRFS, iDFS, or OS, regardless of RS (≤25, 26–30, ≥31).

Key points for clinicians:

No subgroup-by-treatment interaction → RS did not identify a population clearly benefiting from EC-T
HRs hover around 1 across endpoints, with wide CIs due to low event rates
Even in RS ≥31, no clear signal favoring anthracyclines
Results remain consistent after multivariable adjustment

Interpretation matters:

This is not evidence that anthracyclines are obsolete — but it questions their routine use in genomically selected HR+ disease, especially given cardiac and hematologic toxicity.

Take-home:

Anthracyclines may still be reasonable for selected high-risk patients, but genomic risk alone is insufficient to justify their use. Better biomarkers and prospective data are urgently needed to refine escalation strategies.”

Title: A tale of two trials: TAILORx and PlanB. Letter to the Editor regarding “Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/ HER2-negative breast cancer” by Chen et al.